CY1110886T1 - Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση - Google Patents
Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεσηInfo
- Publication number
- CY1110886T1 CY1110886T1 CY20101101012T CY101101012T CY1110886T1 CY 1110886 T1 CY1110886 T1 CY 1110886T1 CY 20101101012 T CY20101101012 T CY 20101101012T CY 101101012 T CY101101012 T CY 101101012T CY 1110886 T1 CY1110886 T1 CY 1110886T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compositions
- normally
- sodium
- gives
- sulbactam
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 2
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 abstract 2
- 229960000479 ceftriaxone sodium Drugs 0.000 abstract 2
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229960000614 sulbactam sodium Drugs 0.000 abstract 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- 108090000204 Dipeptidase 1 Proteins 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000003781 beta lactamase inhibitor Substances 0.000 abstract 1
- 102000006635 beta-lactamase Human genes 0.000 abstract 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229960004755 ceftriaxone Drugs 0.000 abstract 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 229960005256 sulbactam Drugs 0.000 abstract 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 abstract 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Η εφεύρεση περιγράφει σύνθεση για καταπολέμηση της αντοχής στα αντιβιοτικά με μεσολάβηση β-λακταμάσης χρησιμοποιώντας αναστολέα β-λακταμάσης χρήσιμο για ένεση, κατάλληλη για φαρμακευτική εφαρμογή. Η εφεύρεση σχετίζεται με φαρμακευτική σύνθεση που περιέχει κεφτριαξόνη (συνήθως ως νατριούχο κεφρτιαξόνη) και σουλβακτάμη (συνήθως ως νατριούχο σουλβακτάμη). Τέτοιου είδους συνθέσεις αποκαλύπτεται ότι είναι χρήσιμες για ενδομυϊκή ή ενδοφλέβια χορήγηση ως αντιβιοτικά για νοσηλευόμενους ασθενείς που πάσχουν από σοβαρές λοιμώξεις. Συγκεκριμένα, αυτή η εφεύρεση σχετίζεται με φαρμακευτικές συνθέσεις που περιλαμβάνουν περαιτέρω χηλικό παράγοντα αμινοκαρβοξυλικού οξέος, για παράδειγμα, αιθυλενο διαμινο τετραοξικό οξύ (EDTA), ή φαρμακευτικά αποδεκτό άλας αυτού. Οι φαρμακευτικές συνθέσεις αυτής της εφεύρεσης έχει διαπιστωθεί ότι συνήθως ενισχύουν την αντοχή στο σχηματισμό σωματιδίων σε διαλύματα που πρόκειται να χορηγηθούν παρεντερικά. Η εφεύρεση παρέχει επίσης λεπτομέρειες μορφών δόσης που φυλάσσονται σε σφραγισμένα δοχεία για ανασύσταση πριν τη χρήση. Η εφεύρεση παρέχει επίσης διαδικασία παρασκευής των συνθέσεων αυτών. Η εφεύρεση παρέχει μέθοδο θεραπείας ασθενούς που πάσχει από νόσημα ή διαταραχή, όπου ενδείκνυται θεραπεία με νατριούχο κεφτριαξόνη και νατριούχο σουλβακτάμη.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2411DE2004 | 2004-12-02 | ||
| EP05817957A EP1841432B1 (en) | 2004-12-02 | 2005-11-28 | Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110886T1 true CY1110886T1 (el) | 2015-06-10 |
Family
ID=35789266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101101012T CY1110886T1 (el) | 2004-12-02 | 2010-11-10 | Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8273732B2 (el) |
| EP (1) | EP1841432B1 (el) |
| JP (1) | JP5269415B2 (el) |
| KR (2) | KR20070067189A (el) |
| CN (1) | CN101060846A (el) |
| AT (1) | ATE476981T1 (el) |
| AU (1) | AU2005310888B2 (el) |
| BR (1) | BRPI0517128A (el) |
| CY (1) | CY1110886T1 (el) |
| DE (1) | DE602005022939D1 (el) |
| DK (1) | DK1841432T3 (el) |
| ES (1) | ES2349301T3 (el) |
| HR (1) | HRP20100591T1 (el) |
| MX (1) | MX2007006540A (el) |
| NZ (1) | NZ555075A (el) |
| PL (1) | PL1841432T3 (el) |
| PT (1) | PT1841432E (el) |
| RS (1) | RS51506B (el) |
| RU (1) | RU2397768C2 (el) |
| SI (1) | SI1841432T1 (el) |
| UA (1) | UA91204C2 (el) |
| WO (1) | WO2006059344A1 (el) |
| ZA (1) | ZA200704394B (el) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030010176A (ko) * | 2001-07-25 | 2003-02-05 | 이병두 | 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제 |
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| CN101129381B (zh) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| JP5639471B2 (ja) * | 2008-07-28 | 2014-12-10 | 惠三 山口 | 感染症治療効果増強剤 |
| CN101537009B (zh) * | 2009-04-30 | 2010-09-15 | 海口奇力制药股份有限公司 | 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺 |
| JP2012176899A (ja) * | 2009-05-19 | 2012-09-13 | Mitsubishi Tanabe Pharma Corp | ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液 |
| ES2690725T3 (es) * | 2011-05-28 | 2018-11-22 | Wockhardt Limited | Composiciones que comprenden cefepima y tazobactam |
| MX362683B (es) * | 2011-07-26 | 2019-01-31 | Wockhardt Ltd | Composiciones farmacéuticas que comprenden antibiótico de beta-lactama, sulbactama e inhibidor de beta-lactamasa. |
| WO2013042140A2 (en) * | 2011-09-23 | 2013-03-28 | Manu Chaudhary | Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement |
| CA2868390C (en) | 2012-03-26 | 2020-03-31 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising diquafosol |
| KR102083046B1 (ko) | 2012-06-07 | 2020-02-28 | 칠드런＇스 하스피틀 로스 앤젤레스 | 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법 |
| MX2015004039A (es) * | 2012-09-27 | 2015-10-29 | Cubist Pharm Inc | Composiciones de antibiotico de tazobactam arginina. |
| CA2937340C (en) | 2014-02-18 | 2022-06-14 | Children's Hospital Los Angeles | Compositions and methods for treating neutropenia |
| CN106900171A (zh) * | 2014-03-29 | 2017-06-27 | 沃克哈特有限公司 | 包含头孢吡肟或舒巴坦的药物组合物 |
| SG11201509950TA (en) * | 2014-04-03 | 2016-01-28 | Kewpie Kabushiki Kaisha Also Trading As Kewpie Corp | Injection fluid bag and injection preparation |
| US10201518B2 (en) | 2016-09-28 | 2019-02-12 | The University Of Hong Kong | Bismuth(III) compounds and methods thereof |
| JP6891275B2 (ja) * | 2016-11-02 | 2021-06-18 | 湘北威爾曼制薬股▲分▼有限公司Ｘｉａｎｇｂｅｉ Ｗｅｌｍａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ | セフトリアキソンナトリウムとスルバクタムナトリウムからなる組成物 |
| CN106822147B (zh) * | 2016-11-03 | 2021-07-20 | 湘北威尔曼制药股份有限公司 | 一种头孢曲松钠和舒巴坦钠组合物、包含该组合物的药物制剂及其应用 |
| RU2665006C1 (ru) * | 2017-02-28 | 2018-08-24 | Общество с ограниченной ответственностью "Супербаг Солюшенс" | Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| MX2023007135A (es) | 2020-12-17 | 2023-08-25 | Idexx Lab Inc | Detección y tratamiento de la fiebre de las montañas rocosas. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630510B1 (en) * | 1999-10-28 | 2003-10-07 | Merck & Co., Inc. | Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections |
| US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| ES2298672T3 (es) * | 2003-04-14 | 2008-05-16 | Wyeth Holdings Corporation | Composiciones que contienen piperacilina y tazobactam utiles para inyeccion. |
-
2005
- 2005-11-28 PL PL05817957T patent/PL1841432T3/pl unknown
- 2005-11-28 KR KR1020077010375A patent/KR20070067189A/ko not_active Application Discontinuation
- 2005-11-28 AU AU2005310888A patent/AU2005310888B2/en not_active Ceased
- 2005-11-28 KR KR1020097018388A patent/KR101244362B1/ko active IP Right Grant
- 2005-11-28 WO PCT/IN2005/000382 patent/WO2006059344A1/en active Application Filing
- 2005-11-28 PT PT05817957T patent/PT1841432E/pt unknown
- 2005-11-28 DK DK05817957.3T patent/DK1841432T3/da active
- 2005-11-28 EP EP05817957A patent/EP1841432B1/en active Active
- 2005-11-28 MX MX2007006540A patent/MX2007006540A/es active IP Right Grant
- 2005-11-28 AT AT05817957T patent/ATE476981T1/de active
- 2005-11-28 JP JP2007544016A patent/JP5269415B2/ja not_active Expired - Fee Related
- 2005-11-28 BR BRPI0517128-8A patent/BRPI0517128A/pt not_active IP Right Cessation
- 2005-11-28 UA UAA200707280A patent/UA91204C2/ru unknown
- 2005-11-28 DE DE602005022939T patent/DE602005022939D1/de active Active
- 2005-11-28 RS RSP-2010/0465A patent/RS51506B/en unknown
- 2005-11-28 SI SI200531130T patent/SI1841432T1/sl unknown
- 2005-11-28 ES ES05817957T patent/ES2349301T3/es active Active
- 2005-11-28 CN CNA2005800395645A patent/CN101060846A/zh active Pending
- 2005-11-28 NZ NZ555075A patent/NZ555075A/en not_active IP Right Cessation
- 2005-11-28 RU RU2007124325/15A patent/RU2397768C2/ru not_active IP Right Cessation
- 2005-11-28 US US11/720,710 patent/US8273732B2/en not_active Expired - Fee Related
-
2007
- 2007-05-29 ZA ZA200704394A patent/ZA200704394B/xx unknown
-
2010
- 2010-11-03 HR HR20100591T patent/HRP20100591T1/hr unknown
- 2010-11-10 CY CY20101101012T patent/CY1110886T1/el unknown
-
2012
- 2012-09-25 US US13/626,236 patent/US9012442B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20100591T1 (hr) | 2010-12-31 |
| DE602005022939D1 (de) | 2010-09-23 |
| AU2005310888B2 (en) | 2011-01-06 |
| PT1841432E (pt) | 2010-10-25 |
| US20130023512A1 (en) | 2013-01-24 |
| SI1841432T1 (sl) | 2011-02-28 |
| RU2007124325A (ru) | 2009-01-10 |
| KR101244362B1 (ko) | 2013-03-18 |
| RS51506B (en) | 2011-06-30 |
| RU2397768C2 (ru) | 2010-08-27 |
| MX2007006540A (es) | 2008-01-31 |
| DK1841432T3 (da) | 2010-12-06 |
| NZ555075A (en) | 2011-02-25 |
| KR20070067189A (ko) | 2007-06-27 |
| ZA200704394B (en) | 2008-09-25 |
| WO2006059344B1 (en) | 2006-11-02 |
| WO2006059344A1 (en) | 2006-06-08 |
| EP1841432B1 (en) | 2010-08-11 |
| PL1841432T3 (pl) | 2011-01-31 |
| US8273732B2 (en) | 2012-09-25 |
| JP5269415B2 (ja) | 2013-08-21 |
| KR20090101514A (ko) | 2009-09-28 |
| EP1841432A1 (en) | 2007-10-10 |
| US20100160277A1 (en) | 2010-06-24 |
| ATE476981T1 (de) | 2010-08-15 |
| JP2008521884A (ja) | 2008-06-26 |
| BRPI0517128A (pt) | 2008-09-30 |
| AU2005310888A1 (en) | 2006-06-08 |
| UA91204C2 (ru) | 2010-07-12 |
| CN101060846A (zh) | 2007-10-24 |
| US9012442B2 (en) | 2015-04-21 |
| ES2349301T3 (es) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110886T1 (el) | Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση | |
| CO5700796A2 (es) | Composiciones que contienen piperacilina y tazobactam utiles para inyecciones | |
| Martirosov et al. | Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae | |
| JP2018138578A5 (el) | ||
| PE20050438A1 (es) | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos | |
| WO2007112000A3 (en) | Treatment of pain | |
| PT2457926E (pt) | Método para prevenção ou tratamento de uma infecção por m. tuberculosis | |
| TW200639159A (en) | Treatment of pain | |
| TN2009000481A1 (en) | Novel peptide inhibitors of hepatitis c virus replication | |
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| NO20071711L (no) | Sammensetninger inneholdende piperacillin, tazobactam og en aminokarboksylsyre i et natriumlaktat fortynningsmiddel | |
| MX2023013890A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. | |
| JP2008540515A (ja) | 嚢胞性線維症を含む重症感染症の処置および管理 | |
| TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
| CA2633077A1 (en) | Solid-state form of amg 706 and pharmaceutical compositions thereof | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| ATE376422T1 (de) | Diclazurilhaltige antiprotozoenmittel | |
| EA200600377A1 (ru) | Новая композиция | |
| Hamdy et al. | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study | |
| JP6179939B2 (ja) | 高濃度γグロブリン製剤の粘度低下方法 | |
| MX2023009620A (es) | Metodos terapeuticos. | |
| EA200300368A1 (ru) | Применение аргинина при получении лекарственного средства для профилактики и лечения побочных эффектов, связанных с внутривенным введением фармацевтических препаратов | |
| CN1709263A (zh) | 抗菌素组合物 | |
| UA98605C2 (ru) | Новый способ предотвращения или лечения инфекции m. tuberculosis |